Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

The supply of new biotech space in the Bay Area finally is finally starting to slow — but not before sending vacancy rates ...

A well-placed biotech investor says U.S. policies are straining life sciences startups — and more disruption is coming.